Art. -Nr.: HY-10126

Barasertib-HQPA

Name: Barasertib-HQPA
Brand: MedChemExpress
SKU: HY-10126
Price: 55.00 USD
Availability: InStock
Rating: 5 (11 reviews)

(Synonyms: AZD2811; INH-34; AZD1152-HQPA)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.90%
CAS. Nr.: 722544-51-6
Formel: C₂₆H₃₀FN₇O₃
Molecular Weight:507.56

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Barasertib-HQPA Chemical Structure

CAS. Nr.: 722544-51-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

Aurora B

0.37 nM (IC₅₀)

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.1 μM Compound: AAZD1152-HQPA	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 25036791]
A549	IC₅₀	5.4 μM Compound: AAZD1152-HQPA	Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay	[PMID: 25036791]
A549	IC₅₀	8.3 μM Compound: AAZD1152-HQPA	Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay	[PMID: 25036791]
HepG2	IC₅₀	0.1 μM Compound: AAZD1152-HQPA	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 25036791]
HL-60	IC₅₀	12.7 nM Compound: AZD1152	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
MOLM-13	IC₅₀	1 nM Compound: AZD1152-HQPA	Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days	[PMID: 17495131]
MOLM-13	IC₅₀	12 nM Compound: AZD1152-HQPA	Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay	[PMID: 17495131]
MOLM-13	IC₅₀	9.7 nM Compound: AZD1152	Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
MV4-11	IC₅₀	2.8 nM Compound: AZD1152-HQPA	Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days	[PMID: 17495131]
MV4-11	IC₅₀	8 nM Compound: AZD1152-HQPA	Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay	[PMID: 17495131]
MV4-11	IC₅₀	8.6 nM Compound: AZD1152	Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
SW-620	IC₅₀	0.017 μM Compound: 7, AZD-1152 HQPA	Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation	[PMID: 19320489]
THP-1	IC₅₀	25.1 nM Compound: AZD1152	Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]

In Vitro

Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells^[1].
Barasertib-hydroxyquinazoline pyrazol anilide (HQPA) is converted rapidly to the active Barasertib-HQPA in plasma^[2].
Barasertib-HQPA treatment induced defective cell survival, polyploidy, and cell death in LNCaP cell line^[3].
Barasertib-HQPA induces a marked anti-propliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1].

Cell Line:

AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells.
Concentration:

0-100 nM. (Barasertib -HQPA)
Incubation Time:

48 h.
Result:

IC₅₀ values ranged from 3 nM to 40 nM.

In Vivo

Barasertib-HQPA (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors^[1].
Barasertib-HQPA (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts^[1].
Barasertib-HQPA (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to z100%; P < 0.05) in immunodeficient mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS. Nr. 722544-51-6
Appearance Solid
Molecular Weight 507.56
Formel C₂₆H₃₀FN₇O₃
Color White to yellow
SMILES

O=C(CC1=NNC(NC2=C3C=CC(OCCCN(CCO)CC)=CC3=NC=N2)=C1)NC4=CC=CC(F)=C4
Synonyms

AZD2811; INH-34; AZD1152-HQPA
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All IFCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Science

The target landscape of clinical kinase drugs. [Abstract]

2017 Dec 1;358(6367):eaan4368. PMID: 29191878
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Cell Commun Signal

Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis. [Abstract]

2023 Sep 30;21(1):268. PMID: 37777801
Mol Cancer Ther

2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
Int J Mol Sci

Aurora Kinase A Is Involved in Controlling the Localization of Aquaporin-2 in Renal Principal Cells. [Abstract]

2022 Jan 11;23(2):763. PMID: 35054947

Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Jan 11;23(2):763. [Abstract]

MCD4 were left untreated or treated with DMSO (0.3% or 0.2%, 1 h), Alisertib (AURKA inhibitor; 30 µM or 20 µM, 1 h), or Barasertib-HQPA (AURKB inhibitor; 30 µM or 20 µM, 1 h) alone or in combination with forskolin (Fsk; 30 µM, 30 min) or arginine-vasopressin (AVP; 100 nM, 30 min) where indicated. AQP2 was detected by immunofluorescence microscopy. Shown are representative images of four independent experiments; scale bar 30 µm. AQP2 was quantified using a segmentation-based approach. Ratios > 1 indicate a predominant localization at the plasma membrane.
J Cell Sci

An acentrosomal aster with atypical microtubule polarity recruits cytokinesis signals to its center in Xenopus egg extracts. [Abstract]

2025 Sep 1:jcs.263766. PMID: 40888042

Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: J Cell Sci. 2025 Sep 1:jcs.263766. [Abstract]

Confocal images of microtubule dynamics in control extracts (top row) and extracts with 40 µM Aurora kinase B inhibitor Barasertib-HQPA (bottom row). n=6. Each image is a maximum-intensity projection of nine confocal planes spanning 16 µm of depth. Imaging started at an arbitrary time point when asters had just begun to form in the untreated extracts. The results showed that Aurora kinase B inhibition by Barasertib-HQPA abolishes the aster, and the cell-like compartments form with a substantial delay.
J Cell Sci

Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence. [Abstract]

2019 Jul 1;132(13):jcs229385. PMID: 31189537
Exp Cell Res

RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing aurora kinase B mRNA. [Abstract]

2021 Sep 1;406(1):112741. PMID: 34302858

Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2021 Sep 1;406(1):112741. [Abstract]

The IC₅₀ of AURKB inhibitors (AZD1152-HQPA (Barasertib-HQPA, 48 h) and hesperadin) was explored by CCK-8 in gastric cancer cells (MGC-803 and SGC-7901).
bioRxiv

2026 Aug 12.
Ann Transl Med

ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner. [Abstract]

2020 May;8(10):646. PMID: 32566583

Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Ann Transl Med. 2020 May;8(10):646. [Abstract]

The effect of AURKB inhibitor (AZD1152 (Barasertib)-HQPZ (10 μM; 48 h) and hesperidin) on Caki-1 and 786-0 cells with ALKBH5 overexpression was measured by CCK8 and clone formation assays. The colony fold (NC/ALKBH5) is stated under the histogram.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 22 mg/mL (43.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9702 mL

9.8511 mL

19.7021 mL

5 mM

0.3940 mL

1.9702 mL

3.9404 mL

10 mM

0.1970 mL

0.9851 mL

1.9702 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yang, Jing., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep 15;110(6):2034-40. [Content Brief]

[2]. Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13(12):3682-8. [Content Brief]

[3]. Zekri A, et al. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumour Biol. 2015 Feb;36(2):623-32. [Content Brief]

[4]. Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69(10):4150-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9702 mL	9.8511 mL	19.7021 mL	49.2553 mL
	5 mM	0.3940 mL	1.9702 mL	3.9404 mL	9.8511 mL
	10 mM	0.1970 mL	0.9851 mL	1.9702 mL	4.9255 mL
	15 mM	0.1313 mL	0.6567 mL	1.3135 mL	3.2837 mL
	20 mM	0.0985 mL	0.4926 mL	0.9851 mL	2.4628 mL
	25 mM	0.0788 mL	0.3940 mL	0.7881 mL	1.9702 mL
	30 mM	0.0657 mL	0.3284 mL	0.6567 mL	1.6418 mL
	40 mM	0.0493 mL	0.2463 mL	0.4926 mL	1.2314 mL

Bioz

Barasertib-HQPA

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Barasertib-HQPA

Publications Citing Use of MedChemExpress (MCE) Barasertib-HQPA

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen